Low-Endotoxin NAD+ Bulk Supplier: How to Verify ≤0.1 EU/mg

Short answer

“Low endotoxin” should be treated as a lot-specific quality result, not a permanent property of a supplier or a generic purity claim. If a NAD+ powder is marketed at ≤0.1 EU/mg, a buyer should request the report for the actual lot, confirm the bacterial-endotoxins test (BET) method and sensitivity, review interference controls, and match the sample, packaging and storage conditions to the commercial material. A raw-material result does not replace endotoxin, sterility or pyrogen controls required for a finished sterile product.

1. What should a buyer request before approving a low-endotoxin NAD+ lot?

1. Lot identity: NAD+ name, CAS 53-84-9, batch number, production or test date and the exact pack tested.
2. Signed report: a laboratory report or batch COA that states the result in EU/mg, not only “pass” or “low endotoxin.”
3. Test method: gel-clot, kinetic turbidimetric, kinetic chromogenic, or recombinant-reagent BET, together with reagent sensitivity and dilution.
4. Controls: positive product control or inhibition/enhancement data showing that the NAD+ matrix did not suppress or amplify the assay.
5. Traceability: the report, label, shipment and retained sample should all point to the same commercial lot.

2. Why the number alone is not enough

A result of ≤0.1 EU/mg is meaningful only with a stated method, calculation basis and detection capability. NAD+ is a nucleotide coenzyme and the sample matrix, pH, concentration and dilution can affect the BET response. A report without method details makes it difficult to judge whether “not detected” means below 0.1 EU/mg, below a different limit, or simply below the laboratory’s reporting threshold.

For pharmaceutical or diagnostic-reagent development, the finished-product owner should set the acceptance limit from the intended route, dose and regulatory framework. Do not copy a finished injectable limit onto every non-sterile raw-material project, and do not treat a raw-material endotoxin result as proof of sterility.

3. How to review the laboratory method

USP <85> describes gel-clot and photometric BET approaches, while USP <86> covers bacterial-endotoxins testing with recombinant reagents. The method should be suitable for the sample matrix and should include a product-specific interference check. Ask whether the result is reported as an exact value, a limit of quantitation or a pass/fail statement, and whether the laboratory is testing the original powder or a prepared solution.

For a serious qualification review, compare the supplier report with an independent test on the qualification sample. If the two results differ, investigate sample preparation, dilution, reagent lot, analyst, storage and shipping history before approving the batch.

4. Storage and packaging are part of endotoxin control

Endotoxin is not the same as total microbial count, and clean packaging alone does not prove a low result. Confirm how the NAD+ powder is protected from moisture and environmental exposure, how the inner foil pouch is sealed, and whether the outer drum or carton is suitable for the intended shipment. Record the lot number and storage condition when the sample arrives; a delayed test on an opened or poorly stored sample may no longer represent the released material.

5. What PathGene buyers can ask for

PathGene Biotech supplies an endotoxin-controlled NAD+ grade and can discuss the batch-specific third-party report for the intended lot. The NAD+ product page shows the current identity and procurement route. Buyers should state whether the project is non-sterile research, diagnostic-reagent development, pharmaceutical API work or another use, then request the matching specification, sample, packaging information and signed COA. For a broader review of identity, purity, elemental impurities and microbiology, see our NAD+ bulk quality review and the quality-document request page.

Evidence boundary

A ≤0.1 EU/mg result supports qualification of the tested raw-material lot. It does not establish sterility, absence of all pyrogens, finished-product safety or regulatory approval. Acceptance limits and release testing must be set for the actual application and destination market.

References

FDA, Pyrogen and Endotoxins Testing: Questions and Answers; USP <85> Bacterial Endotoxins Test; USP <86> Bacterial Endotoxins Test Using Recombinant Reagents.